Kaveri Pohlman
Stock Analyst at Clear Street
(0.18)
# 4,318
Out of 4,969 analysts
22
Total ratings
14.29%
Success rate
-32.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Initiates: Buy | $32 | $19.26 | +66.15% | 1 | Jun 25, 2025 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.91 | - | 4 | Aug 1, 2024 | |
| GMAB Genmab | Maintains: Buy | $46 → $47 | $27.08 | +73.56% | 3 | Jun 27, 2024 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $20 → $30 | $7.72 | +288.60% | 2 | Apr 17, 2024 | |
| XNCR Xencor | Maintains: Buy | $56 → $38 | $8.33 | +356.18% | 1 | Apr 16, 2024 | |
| NUVB Nuvation Bio | Upgrades: Buy | $5 | $3.15 | +58.73% | 2 | Mar 26, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $62 | $23.04 | +169.10% | 1 | Mar 21, 2024 | |
| PYXS Pyxis Oncology | Initiates: Buy | $8 | $1.47 | +444.22% | 1 | Feb 9, 2024 | |
| EXEL Exelixis | Initiates: Buy | $27 | $36.96 | -26.95% | 1 | Dec 19, 2023 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $70 | $11.64 | +501.37% | 1 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.28 | +837.50% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $2.12 | +277.36% | 2 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12,320 → $4,928 | $3.13 | +157,344.09% | 2 | Feb 9, 2022 |
ArriVent BioPharma
Jun 25, 2025
Initiates: Buy
Price Target: $32
Current: $19.26
Upside: +66.15%
MacroGenics
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.91
Upside: -
Genmab
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $27.08
Upside: +73.56%
Cullinan Therapeutics
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $7.72
Upside: +288.60%
Xencor
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $8.33
Upside: +356.18%
Nuvation Bio
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $3.15
Upside: +58.73%
Janux Therapeutics
Mar 21, 2024
Initiates: Buy
Price Target: $62
Current: $23.04
Upside: +169.10%
Pyxis Oncology
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $1.47
Upside: +444.22%
Exelixis
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $36.96
Upside: -26.95%
Arcus Biosciences
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $11.64
Upside: +501.37%
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $1.28
Upside: +837.50%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $2.12
Upside: +277.36%
Feb 9, 2022
Maintains: Buy
Price Target: $12,320 → $4,928
Current: $3.13
Upside: +157,344.09%